TABLE 2.
Effect of triazoles on coadministered drugs
| Coadministered drug |
Effects of triazoles on coadministered drugs
|
|||
|---|---|---|---|---|
| Voriconazole | Posaconazole | Itraconazole | Fluconazole | |
| Cyclosporine (CSA) ↑ concentrations | Dose of CSA should be reduced to one-half of the original dose | Dose of CSA should be reduced to three-quarters of the original dose | Dose of CSA may require a 50% reduction | Careful monitoring of immunossupressive drugs is advised |
| Tacrolimus (TAC) ↑ concentrations | Dose of TAC should be reduced to one-third of the original dose | Dose of TAC should be reduced to one-third of the original dose | Dose of TAC may require a one-third reduction | |
| Sirolimus (SIR) ↑ concentrations | Coadministration contraindicated | Theoretically monitor SIR concentrations | Dose of SIR may require 50% to 90% reduction | |
| Rifabutin ↑ concentrations | Coadministration contraindicated | Coadministration contraindicated | Coadministration contraindicated | Coadministration is not advised |
| Phenytoin ↑ concentrations | Frequent monitoring of phenytoin levels is recommended | Dosage reduction may be considered. Frequent monitoring of phenytoin levels is recommended | ||
| Ergot alkaloids ↑ concentrations | Coadministration contraindicated | Coadministration contraindicated | Coadministration contraindicated | Coadministration contraindicated |
| Vinca alkaloids ↑ concentrations | Use with caution, following a 48 h wash-out period | Use with caution, following a 48 h wash-out period | Use with caution, following a 48 h wash-out period | Dosage adjustment for vinca alkaloids may be necessary |
| HMG-CoA reductase inhibitors (statins) ↑ concentrations | Statin dosage reduction may be necessary. Frequent monitoring for ADRs (rhabdomyolysis) is recommended | |||
| Dihydropiridine calcium channel blockers (CCB) ↑ concentrations | Monitor for signs of CCB toxicity. Dosage reduction may be necessary | |||
| HIV protease inhibitors ↑ concentrations | Check individual agent. Monitor for signs of protease inhibitor toxicity | |||
| Sulfonylurea oral hypoglycemics ↑ concentrations | Sulfonylurea dosage reduction may be necessary. Monitor for signs of hypoglycemia | – | – | – |
| Midazolam ↑ concentrations | Frequent monitoring of oversedation is recommended | Dosage reduction should be considered | Contraindicated | Careful monitoring is advised |
↑ Increase; HMG-CoA 3-hydroxy-3-methyl-glutaryl-coenzyme A